0001558370-24-015779.txt : 20241115 0001558370-24-015779.hdr.sgml : 20241115 20241115073032 ACCESSION NUMBER: 0001558370-24-015779 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20241115 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241115 DATE AS OF CHANGE: 20241115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-PATH HOLDINGS, INC. CENTRAL INDEX KEY: 0001133818 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 870652870 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36333 FILM NUMBER: 241465850 BUSINESS ADDRESS: STREET 1: 4710 BELLAIRE BOULEVARD STREET 2: SUITE 210 CITY: BELLAIRE STATE: TX ZIP: 77401 BUSINESS PHONE: (832) 742-1357 MAIL ADDRESS: STREET 1: 4710 BELLAIRE BOULEVARD STREET 2: SUITE 210 CITY: BELLAIRE STATE: TX ZIP: 77401 FORMER COMPANY: FORMER CONFORMED NAME: BIO-PATH HOLDINGS INC DATE OF NAME CHANGE: 20080221 FORMER COMPANY: FORMER CONFORMED NAME: OGDEN GOLF CO CORP DATE OF NAME CHANGE: 20010205 8-K 1 bpth-20241115x8k.htm 8-K
0001133818false00011338182024-11-152024-11-15

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

​

FORM 8-K

​

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

​

Date of report (Date of earliest event reported): November 15, 2024

​

BIO-PATH HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

​

​

​

Delaware

    

001-36333

    

87-0652870

(State or other jurisdiction of incorporation)

​

(Commission File Number)

​

(IRS Employer Identification No.)

​

​

​

4710 Bellaire Boulevard, Suite 210, Bellaire, Texas

    

77401

(Address of principal executive offices)

​

(Zip Code)

​

(832) 742-1357

(Registrant’s Telephone Number, Including Area Code)

​

(Former Name or Former Address, if Changed Since Last Report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class

    

Trading Symbol

    

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

BPTH

 

The Nasdaq Capital Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

​

​

​

Item 2.02 Results of Operations and Financial Condition.

​

The information in this Current Report on Form 8-K (this “Current Report”) is being furnished pursuant to Item 2.02 of Form 8-K and, according to general instruction B.2. thereunder, the information in this Current Report shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended.

​

On November 15, 2024, Bio-Path Holdings, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended September 30, 2024. Additional information is included in the Company’s press release. A copy of the Company’s press release is attached hereto as Exhibit 99.1. The foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.

​

Item 9.01 Financial Statements and Exhibits.

​

(d) Exhibits.

​

Exhibit

 

 

Number

 

Description

 

 

 

99.1

 

Press release dated November 15, 2024.

104

​

The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101).

​

​

​

​

​

​

​

​

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

​

 

BIO-PATH HOLDINGS, INC.  

 

 

 

​

​

​

Dated: November 15, 2024

By:

/s/ Peter H. Nielsen

 

 

Peter H. Nielsen

 

 

President and Chief Executive Officer

​

​

 EX-99.1 2 bpth-20241115xex99d1.htm EX-99.1

Exhibit 99.1

Graphic

​

Bio-Path Holdings Reports Third Quarter 2024 Financial Results

​

Expands DNAbilize® Technology Beyond Oncology into Obesity

​

Conference Call to be Held Today at 8:30 A.M. ET

​

HOUSTON—November 15, 2024 – Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2024 and provided an update on recent corporate developments.

​

“The third quarter was a particularly productive period for Bio-Path as we initiated our obesity program, which marks the first application of our DNAbilize® platform beyond oncology and highlights its broad therapeutic potential," said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. "Importantly, we continued to advance our oncology programs and were delighted with the swift enrollment of the third cohort in our Phase 1/1b clinical trial of BP1002 in venetoclax-resistant AML patients, which was ahead of our projected timelines.  We also published an article highlighting the broad anti-tumor effect of BP1003 in numerous preclinical solid tumor models, including breast, ovarian, and pancreatic cancer, in the peer-reviewed journal, Biomedicines.”  

​

Recent Corporate Highlights

​

●Initiated BP1001-A Therapeutic Program for Treatment of Obesity. In October, the Company announced the initiation of a therapeutic program to develop BP1001-A for the treatment of obesity and related metabolic diseases. This program marks the first application of DNAbilize® technology for development of a non-cancer application, which highlights the broad therapeutic potential of this technology. The disease pathology leading to obesity suggests that BP1001-A, which suppresses the adaptor protein Grb2, has the potential to treat insulin resistance, a major contributor to obesity, Type 2 diabetes and other related metabolic diseases. Bio-Path expects downregulating Grb2 expression with BP1001-A will enhance insulin sensitivity.

​

●Completion of Enrollment for Third Dosing Cohort of Phase 1/1b Clinical Trial of BP1002 in Venetoclax-Resistant Acute Myeloid Leukemia (AML) Patients. In October, Bio-Path announced completion of enrollment for the third dosing cohort of the Company’s Phase 1/1b trial of BP1002 in venetoclax-resistant AML patients. The cohort enrolled more quickly than projected, which underscores the ongoing need for new treatment options for these relapsed/refractory patients.

​

●Publication in Peer-Reviewed Journal, Biomedicines. In September, Bio-Path published an article highlighting the therapeutic potential of BP1003 in a variety of cancer types in the peer-reviewed journal, Biomedicines. The article describes the broad anti-tumor effect of BP1003 in numerous preclinical solid tumor models including breast, ovarian, and pancreatic cancer. BP1003 is a neutral liposome incorporated with a nuclease resistant P-ethoxy antisense oligodeoxynucleotide targeting the STAT3 mRNA and its unique design enhances stability, cellular uptake, and target affinity.

​

●Reported Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors. Bio-Path’s first patient in the second dose cohort in its Phase 1/1b advanced solid tumor clinical trial experiencing a positive response may signal that this analog of prexigebersen has potential as a new treatment for advanced solid tumors. The patient appears to be doing well on study after failing extensive chemotherapy and surgical treatment for gynecologic cancer, demonstrating a 15% reduction in her primary tumor through six cycles of treatment. Moreover, it appears that these positive outcomes may have contributed to allow her to continue with rigorous exercise and improved quality of life.

​

The dose finding portion of the Phase 1/1b trial is comprised of BP1001-A monotherapy with no accompanying chemotherapy. This clinical trial of BP1001-A in patients with advanced or recurrent solid tumors has successfully completed the initial prescribed dose in the first cohort of 60 mg/m2 and began enrollment in the higher dose cohort of 90 mg/m2. The Phase 1b portion of the study is expected to commence after completion of three planned BP1001-A monotherapy dose level cohorts and is intended to assess the safety and efficacy of BP1001-A in combination

with paclitaxel in patients with recurrent ovarian or endometrial tumors. Phase 1b studies are also expected to be opened in combination with gemcitabine in late-stage pancreatic cancer.

​

●Closed $4.0 Million Private Placement. In October, Bio-Path announced closing of a private placement priced at-the-market under Nasdaq rules for the issuance and sale of an aggregate of 4,597,702 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 6,407,657 shares of common stock and short-term series B warrants to purchase up to 6,407,657 shares of common stock at a purchase price of $0.87 per share of common stock (or per common stock equivalent in lieu thereof) and accompanying warrants in a private placement. The gross proceeds to the Company from the offering were approximately $4.0 million, before deducting the placement agent’s fees and other offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the warrants.

​

Financial Results for the Third Quarter Ended September 30, 2024

​

●The Company reported a net loss of $2.1 million, or $0.70 per share, for the three months ended September 30, 2024, compared to a net loss of $3.2 million, or $6.36 per share, for the three months ended September 30, 2023.

​

●Research and development expense for the three months ended September 30, 2024 decreased to $1.3 million, compared to $2.3 million for the three months ended September 30, 2023 primarily due to decreased manufacturing expenses related to drug product releases as well as a decrease in expense related to our clinical trial for BP1001 in AML due to timing of patient enrollment during the quarter.

​

●General and administrative expense for the three months ended September 30, 2024 increased to $1.3 million, compared to $1.0 million for the three months ended September 30, 2023 primarily due to increased legal fees and salaries and benefits expense.

​

●As of September 30, 2024, the Company had cash of $0.6 million, compared to $1.1 million as of December 31, 2023. Net cash used in operating activities for the nine months ended September 30, 2024 was $7.7 million compared to $9.7 million for the comparable period in 2023. Net cash provided by financing activities for the nine months ended September 30, 2024 was $7.2 million.

​

Conference Call and Webcast Information

​

Bio-Path Holdings will host a conference call and webcast today at 8:30 a.m. ET to review these third quarter 2024 financial results and to provide a general update on the Company. To access the conference call please dial (844) 481-3014 (domestic) or (412) 317-1879 (international). A live audio webcast of the call and the archived webcast will be available in the Media section of the Company’s website at www.biopathholdings.com.

​

About Bio-Path Holdings, Inc.

​

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1/1b study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.

​

For more information, please visit the Company's website at www.biopathholdings.com.  

​

Forward-Looking Statements

​

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These statements are based on management's current expectations and accordingly are subject to uncertainty and changes in circumstances. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Bio-Path’s ability to raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies, the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, the maintenance of intellectual property rights, that patents relating to existing or future patent

applications will be issued or that any issued patents will provide meaningful protection of our drug candidates, the impact, risks and uncertainties related to global pandemics, including the COVID-19 pandemic, and actions taken by governmental authorities or others in connection therewith, and such other risks which are identified in Bio-Path's most recent Annual Report on Form 10-K, in any subsequent quarterly reports on Form 10-Q and in other reports that Bio-Path files with the Securities and Exchange Commission from time to time. These documents are available on request from Bio-Path or at www.sec.gov. Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

​

# # #

​

Contact Information:

​

Investors

​

Will O’Connor

Stern Investor Relations, Inc.

212-362-1200

will@sternir.com

​

Doug Morris

Investor Relations

Bio-Path Holdings, Inc.

832-742-1369

 GRAPHIC 3 bpth-20241115xex99d1001.jpg GRAPHIC begin 644 bpth-20241115xex99d1001.jpg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end EX-101.SCH 4 bpth-20241115.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 bpth-20241115_lab.xml EX-101.LAB EX-101.PRE 6 bpth-20241115_pre.xml EX-101.PRE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Document and Entity Information
Nov. 15, 2024
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Nov. 15, 2024
Entity File Number 001-36333
Entity Registrant Name BIO-PATH HOLDINGS, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 87-0652870
Entity Address State Or Province TX
Entity Address, Address Line One 4710 Bellaire Boulevard
Entity Address, Adress Line Two Suite 210
Entity Address, City or Town Bellaire
Entity Address, Postal Zip Code 77401
City Area Code 832
Local Phone Number 742-1357
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol BPTH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001133818
Amendment Flag false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports bpth-20241115.xsd bpth-20241115_lab.xml bpth-20241115_pre.xml bpth-20241115x8k.htm http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bpth-20241115x8k.htm": { "nsprefix": "bpth", "nsuri": "http://www.biopathholdings.com/20241115", "dts": { "schema": { "local": [ "bpth-20241115.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "labelLink": { "local": [ "bpth-20241115_lab.xml" ] }, "presentationLink": { "local": [ "bpth-20241115_pre.xml" ] }, "inline": { "local": [ "bpth-20241115x8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_11_15_2024_To_11_15_2024_8aDumQ1E_0mUmXRIw2g2ZQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "bpth-20241115x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_11_15_2024_To_11_15_2024_8aDumQ1E_0mUmXRIw2g2ZQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "bpth-20241115x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Adress Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001558370-24-015779-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-015779-xbrl.zip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end XML 17 bpth-20241115x8k_htm.xml IDEA: XBRL DOCUMENT 0001133818 2024-11-15 2024-11-15 0001133818 false 8-K 2024-11-15 BIO-PATH HOLDINGS, INC. DE 001-36333 87-0652870 4710 Bellaire Boulevard Suite 210 Bellaire TX 77401 832 742-1357 false false false false Common Stock, par value $0.001 per share BPTH NASDAQ false